Clinically known as benign prostatic hyperplasia (BPH), enlarged prostate is a non‑cancerous condition that affects roughly half of men ages 51 to 60, with incidence increasing ...
Vanquish uses ultrasound, transurethral and electromagnetically guided thermotherapy to ablate prostate tissue.
Profound Medical Corp. (NASDAQ:PROF) Q4 2025 Earnings Call Transcript March 6, 2026 Operator: Good day, and thank you for standing by. Welcome to the Profound Medical Fourth Quarter 2025 Financial ...
Metastatic prostate cancer is currently associated with high morbidity and mortality rates. In addition, patients respond very differently to standard treatments such as hormone therapy or radiation ...
The FDA has approved a new formulation of an F 18 prostate-specific membrane antigen imaging agent for men with prostate cancer, according to an industry press release. As Healio previously reported, ...
The U.S. Food and Drug Administration on Friday approved a new ​formulation of Lantheus Holdings' prostate cancer imaging agent, aimed at improving ‌scanning access through increased production ...
The patient and local surgical team were located in Gibraltar, about 2,400 kilometers (about 1,500 miles) away. The procedure ...
The milestone procedure saw Professor Prokar Dasgupta, based at The London Clinic's robotic center in Harley Street, operate ...
Axogen, Inc. (AXGN) 47th Annual Raymond James Institutional Investor Conference March 3, 2026 3:25 PM ESTCompany ParticipantsMichael Dale - President, ...
Arun Menawat, Chairman & CEO, emphasized the completion of recruitment for CAPTAIN, the first multicenter, randomized, controlled trial comparing a new technology to robotic radical prostatectomy, ...
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (“iMRI”) procedures, ...
When a doctor suspects bladder cancer, they will order a series of tests which may include urine tests (urinalysis or urine ...